Nektar Therapeutics (NKTR), which announced this morning that efficacy data previously generated by Eli Lilly (LLY) for rezpegaldesleukin that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly, has filed a complaint in San Francisco federal court that accuses Lilly of breach of contract, negligent misrepresentation, unfair competition and other wrongdoing, reported Reuters. Nektar seeks compensatory and punitive damages, among other remedies, the report noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NKTR: